Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.

MLA

Gong, Jun, et al. “Phase I Trial of Bermekimab with Nanoliposomal Irinotecan and 5-Fluorouracil/Folinic Acid in Advanced Pancreatic Ductal Adenocarcinoma.” Scientific Reports, vol. 12, no. 1, Sept. 2022, p. 15013. EBSCOhost, https://doi.org/10.1038/s41598-022-19401-3.

APA

Gong, J., Thomassian, S., Kim, S., Gresham, G., Moshayedi, N., Ye, J. Y., Yang, J. C., Jacobs, J. P., Lo, S., Nissen, N., Gaddam, S., Tighiouart, M., Osipov, A., & Hendifar, A. (2022). Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Scientific Reports, 12(1), 15013. https://doi.org/10.1038/s41598-022-19401-3

Chicago

Gong, Jun, Shant Thomassian, Sungjin Kim, Gillian Gresham, Natalie Moshayedi, Jason Y Ye, Julianne C Yang, et al. 2022. “Phase I Trial of Bermekimab with Nanoliposomal Irinotecan and 5-Fluorouracil/Folinic Acid in Advanced Pancreatic Ductal Adenocarcinoma.” Scientific Reports 12 (1): 15013. doi:10.1038/s41598-022-19401-3.